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Abstract
Personalized treatments have become a primary goal in translational psychiatric research. They include the
identification of neural circuits associated with psychiatric disorders and definition of treatment according to
individual characteristics. Many new tools and technologies have been developed but further efforts are required to
provide clues on how these scientific advances in psychiatry may be translated into more effective therapeutic
approaches. Obstacles to the progress of translational psychiatry also involve numerous scientific, financial, ethical,
logistics and regulatory aspects. Also, the goal of DSM-5 to expand “signs and symptoms” classification to
incorporate biological measures may help the development of new multifactorial and dimensional models able to
better understand the pathophysiology of psychiatric disorders and develop improved treatments. Finally, a better
understanding on the significant response variability, cognitive functioning, role of comorbidities and treatment-
resistant cases are critical for the development of prevention and intervention strategies that are more effective.
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Introduction
Translational research is at the forefront of contempor-
ary psychiatric research. The term “translational” was
first cited in the PubMed in 1993, characterizing the gene
BRCA1 and its immediate applications in early detection
and treatment of breast cancer [1]. This definition was
cited few times throughout the 1990s until 2000, when
the term started to be quoted in hundreds of articles
every year. Although the term "translational" has various
definitions, all focus on a better understanding of the
pathophysiology and development of new diagnostic
tests, aiming to develop better treatments for specific
diseases.
The term translational can be also characterized as the
process of obtaining benefit for patients by converting
scientific discoveries from preclinical research into clin-
ical applications, with the goal of improving health para-
meters, consequently decreasing morbidity and mortality
[2]. Translational research also refers to those activities
conducted to bridge the gap between drug discovery in
preclinical models and drug development in humans. It
has been used to refer to the entire enterprise of medi-
cine: “from bench to bedside and from bedside to bench”
[3,4].
Historically, in the 1950s and '60s, basic and clinical
researches were largely interconnected in research insti-
tutions such as the National Institutes of Health (NIH),
USA and academic institutions worldwide. Biomedical
research was performed mostly in laboratories by med-
ical scientists, who also treated patients. In the 1970s,
this model was adapted due to the rapid development of
molecular biology techniques. In this period, clinical and
basic research began to be put apart as two distinct areas
of research, also having different staff members. Since
that period, most of the biomedical preclinical research
(currently considered translational) has been developed
by highly skilled PhDs scientists, while physicians lack-
ing or with limited preclinical background have been
only conducting clinical studies. Thus, a translational gap
has arisen, which means that clinical neuroscience re-
search, previously conducted by physician-scientists, be-
came scarce and limited the communication between
basic and clinical scientists.
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Besides, other gaps have been identified in transla-
tional research. For example, in 2006, a study by Cook-
sey [5] was hired to conduct an independent assessment
on the public funding for health research in the United
Kingdom (UK). The report identified two major issues.
First, the difficulty to transform basic and clinical re-
search into integrated ideas, concepts and products. An
additional gap described refers to the difficulty in trans-
lating these ideas, concepts and products into better out-
comes and improved treatments for clinical practice. In
the same year, the NIH introduced the "Bench to Bed-
side" award, aiming to encourage collaborations between
physicians and basic scientists at different NIH intra-
mural institutes. Other similar public and private initia-
tives on a larger scale have been developed in recent
years, such as the "FDA Critical Path" and the "NIMH
Strategic Plan" [6]. The NIH Road Map, with a total
budget estimated at 10 billion dollars, was created to
provide scientists with the technologies and human re-
sources to enable the more efficient translation, also
supporting institutional infrastructure for research cen-
ters and departments focusing on translational medicine.
Similar initiatives have been developed in diverse coun-
tries. These projects aim to introduce innovative tools in
pharmacology, machineries and clinical methods able to
improve our understanding on the pathophysiological
mechanisms and to develop new and better treatments.
They also objective to increase efficacy rates of clinical
trials phase 2 [2], which involves continuous investiga-
tion of potential therapeutic targets and biomarkers in
humans, as well as the evaluation of therapeutic index
and cost-effectiveness parameters.
Translational research in psychiatry directly involves
the concept of personalized medicine, which aims to
identify the more accurate individual treatment, based
on clinical, genetic, genomic and environmental infor-
mation. In the last decade, progresses in this area have
directly involved the validation of new biomarkers with
potential clinical relevance. This area has provided a
wide range of scientific progresses using tools and tech-
nologies, which integrate basic research information with
clinical practice. These biomarkers target on the meas-
urement of physiological and pathological processes, as
well as focus on the prediction of pharmacological re-
sponse to a particular treatment [7].
Biomarkers are cornerstones in the discovery and de-
velopment of new treatments, ranging from preclinical
studies to clinical trials. In 1998, the NIH Biomarkers
Definitions Working Group defined a biomarker as “a
characteristic that is objectively measured and evaluated
as an indicator of normal biological processes, patho-
genic processes, or pharmacologic responses to a thera-
peutic intervention [8]. Another important definition is
surrogate biomarker, characterized as “a laboratory or
physical sign that is used in therapeutic trials as a substi-
tute for a clinically meaningful endpoint, that is a meas-
ure of a how a patient feels, functions, or survives and
that is expected to predict the effect of therapy”.
Whereas surrogate biomarkers substitute for clinical
endpoints, other biomarkers are only adjunct to clinical
endpoints [3,4].
Biomarkers aim to provide evidences supporting the
concept that certain targets have therapeutic relevance
in psychiatric disorders. Discovery, validation and appli-
cation of biomarkers at all stages of drug development
involve different steps. In the search of a new effective
compound and identification of its targets (e.g. biomar-
kers), preclinical studies are followed by clinical safety
studies (Phase 1) and efficacy and tolerability (Phase 2
and 3) (Figure 1). Subsequently, Phase 4 involves post-
approval studies after marketing the drug to explore
other indications, also evaluating effectiveness and safety
in daily clinical practice. However, Phase 4 studies do
not provide relevant answers in translational research
and drug development in psychiatric research.
The pursuit of scientifically based therapeutic decision
can be considered a key objective in translational research
in psychiatry. Nevertheless, despite these recent advances,
only few agents commercially available have arisen from
these translational strategies in psychiatry in the last dec-
ade, associated with diverse challenges and barriers. For
instance, lack of funding, high costs, inadequate samples
and conflicts of interest are common limitations. Fur-
thermore, fragmented infrastructure, shortage of quali-
fied researchers, incompatible databases and lack of
technical support are important barriers to be overcome
in order to increase effectiveness in translational psychi-
atric research.
At the same time, new methods and disciplines in
translational psychiatry have increased the number of
new potential therapeutic strategies in the continuum
bench to bedside. Recent advances in genomics, proteo-
mics, metabolomics and others have provided advances
ad promising perspectives in this area. The model pro-
posed by the National Institute of Mental Health (NIMH)
reinforces the need to identify neural circuits associ-
ated with psychiatric disorders, as well as to detect early
manifestations associated with increased risk for ill-
ness, even before the onset of cognitive and behavioral
changes. This model also aims to customize services
based on individual responses, as well as foster the opti-
mized use of effective psychosocial interventions [6].
Other examples of initiatives in translational psychiatry
include the National Institutes for Health Research
(NIHR) and industry cooperation to create standar-
dized batteries for assessment of effects of treatments
on cognition, such as the MATRICS initiative in schiz-
ophrenia [9].
Machado-Vieira Journal of Translational Medicine 2012, 10:175 Page 2 of 7
http://www.translational-medicine.com/content/10/1/175
There is a recent trend in translational psychiatry to
define at risk populations studying surrogate populations
(e.g. relatives of patients or patients with mild forms of
the disorder). This approach provides the opportunity
for small proof-of-concept Phase 1 trials of novel medi-
cations [4,10,11]. For instance, the evaluation of surro-
gate populations in clinical trials includes subjects with
schizotypal personality instead of schizophrenia [9]. An-
other development is the use of pharmacological agents
to induce states that mimic some of the disease features
in healthy volunteers (e.g. drug-induced psychoses with
amphetamine) [12]. Schizotypal personality presents
cognitive deficits, positive and negative symptoms and
anhedonia, also considered a risk factor for psychosis
[13]. Another example includes neurokinin NK1 antago-
nists, which showed promising trends in preclinical and
initial clinical studies, but not subsequently replicated in
Phase 3 trials [14,15].
However, the implementation of this approach still
requires adaptation of the currently used phase 1
scheme, and could have a significant impact on the suc-
cess rates of clinical research in psychiatry. Overall, these
approaches may help to limit erroneous therapeutic indi-
cation and/or in incorrect doses by testing the likelihood
that a drug would be effective in patients and represent
a valuable model of psychiatric disorders in Phase 1
trials [12,16].
Challenges in translational research in psychiatry
The development of a new treatment may take up to
20 years. Obstacles to the progress of psychiatry also in-
volve numerous scientific, financial, ethical, logistics and
regulatory issues. Translational approaches in other
areas of medicine seem much more developed than
psychiatry. In oncology, for example, available biomar-
kers have been clearly associated with course, prognosis
and treatment response. Furthermore, in many cases,
they strongly guide the therapeutic decision. Meanwhile,
psychiatric disorders present heterogeneous symptom-
atology, cognitive functioning and comorbidities, also in-
volving a wide range of genetic and environmental risk
factors. Thus, translation has a high level of complexity
and encompasses a very long path from basic neuros-
ciences to patient care.
In the last decades, preclinical research in psychiatry
has arisen due to the obvious inaccessibility of human
brain in vivo for biochemical and molecular studies. It is
important to mention that basic research, especially ani-
mal models, may help to limit the number of potential
drug candidates that may fail in human trials. Animal
-animal models
-basic research in
vivo, in vitro
-development of 
new compounds
BASIC RESEARCH
CLINICAL RESEARCH
TRANSLATIONAL 
RESEARCH (phase I)
Cases series
Clinical trial phase 1 e2-
Proof of concept trials
State and trait biomarkers, 
surrogate oucomes
New tools/technologies
Bioinformatics
Clinical research phase 3
-From clinical research 
to medical care
-New public health 
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-Priorities: Prevention 
and intervention
TRANSLATIONAL 
RESEARCH (phase II)
Figure 1 Interface between basic and clinical research in mood disorders translational research, divided in phase I (translacional
research per se) e phase II (translating research advances into population benefits and improved health system). Translational research in
psychiatry involves the development of useful animal behavioral models of psychiatric disorders and preclinical in vitro/vivo studies using brain
cells. These are the first steps to test new compounds, which evaluate potential mechanisms of action and behavioral effects, focusing on the
evaluation of predictive validity. When validated, these new agents are tested in phase 1 translational studies (pharmacokinetics, dose and
tolerability), which together with clinical trial phase 2 studies (proof of concept trial evaluating efficacy). These two step use new tools and other
technological advances (e.g. bioinformatics), also searching for potential biomarkers (preferentially in early phases). The next step in the
translational paradigm involves the approval in phase 3 and posterior application of new public health policies focusing on prevention and early
intervention in mental disorders.
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models in psychiatric research use a neurobiological tool
or a disease model, involving an ample range of behav-
ioral assays [17]. However animal models still have sev-
eral limitations per se. For instance, it is challenging to
translate higher cognitive functions and complex affec-
tive states (e.g. the switch process in bipolar disorder)
[18] that differentiate humans from animals [19]. Besides,
with the advent of recent techniques in human studies
including neuroimaging in vivo studies (e.g. positron
tomography-PET, proton spectroscopy-MRS), animal
models have been gradually competing with new techni-
ques able to directly evaluate human samples.
Noteworthy, recent advances on techniques and tools
for human translational studies come from the field of
genetics, neuroimaging, psychopharmacology, neuro-
physiology, neuropathology, with special relevance for
the fronto-striatal-limbic structures and their functions.
Despite current development, other potential therapeutic
targets than monoamines in translational psychiatric re-
search are still scarce; studies on potential new drugs
that would exert their therapeutic effects by targeting
identified pathways and circuits using cellular and mo-
lecular biology studies require further examination, in-
cluding the use of human genome sequencing and high
throughput technologies. New targets beyond mono-
amines have been associated with rapid onset of thera-
peutic actions and improvement in treatment-resistant
cases [20]. These new targets include CRF and gluco-
corticoids receptor antagonists, vasopressin receptor
antagonists, glutamate modulators, opioid receptor mod-
ulators, histone deacetylase inhibitors, among others
[21,22]. Potential reasons limiting the progression of new
treatments from basic research to clinical include signifi-
cant behavioral of a compound effect only in animals but
not in humans, treatment given to the wrong subject
(diagnosis) and inadequate dose [3,4]. It is important to
mention that many treatments showing efficacy in certain
psychiatric disorders were first clinically used for other
indications (e.g. anticonvulsants in bipolar disorder).
In the same context, the study of endophenotypes may
be considered a strategic area in translational research
and drug development in psychiatry. Endophenotypes
involve the identification of “downstream” traits or facets
of clinical phenotypes, as well as the “upstream” conse-
quences of genetic vulnerability to specific psychiatric
disorders [23]. Endophenotypes characterize more stable
phenotypes with a clear genetic connection (not involv-
ing symptoms that fluctuate over time).
Drug discovery in psychiatry has recently focused on
the mechanisms underlying cellular vulnerability and re-
silience targeting beyond monoamines. These new trans-
lational approaches in psychiatry may stimulate the
called 'fishing expedition'. Instead of using the classical
hypothesis-driven approach, they focus on hypotheses-
generating experiments, which are much broader and
sometimes even difficult to interpret. However, at the
same time, this new approach might provide the iden-
tification of new potential therapeutic targets beyond
monoamines. The question whether expanding, using
“fishing expedition” aiming to discover unexpected key
therapeutic targets or limiting using hypothesis-driven
studies remains controversial. Since 80% of human
25,000 genes have some effect on the brain, the use of
hypothesis-generating approaches may increase the level
of complexity [24]. In this context, recent studies have
generated such a volume of potential new targets that
the pharmaceutical industry and academic centers are
having trouble "digesting" all new data, not being able
yet to fully “sift the wheat from the chaff."
It has been also emphasized the importance to design
clinical trials that estimate chances of success in initial
clinical development, proposed as “quick win, quick kill”
(Eli Lilly); this concept focus on the early identification
of molecules that will potentially fail or those having the
greatest potential for success in phase 1 or early phase 2
[25]. Biomarkers also play a critical role in this strategy.
In drug development by pharmaceutical industry, the
main reason of trial failure is lack of efficacy and safety
issues, responsible for approximately 30% and 20% re-
spectively of all failure [26]. Also, a reduced rate of re-
turn on investment has led a number of pharmaceutical
companies to cut expenses and limit new projects on
psychiatry as a therapeutic area. Two major companies,
GlaxoSmithKline and AstraZeneca [27], recently reduced
significantly basic research aimed at developing new
agents for psychiatric disorders.
Pioneering studies identifying loss of neuroprotection
(neurons and glial cells) in psychiatric disorders involve
dysfunction in multiple neurotransmitter systems, sec-
ond messengers and gene expression. Postmortem brain
studies, animal models and central (CSF) and peripheral
biomarkers have provided important knowledge in the
context of neuroplasticity. These targets may involve the
use of approaches such as cell biology (cell membrane
and organelles) and molecular (second messengers and
signal transduction) tools. Also, changes in neurotrophic
factors, oxidative stress parameters, inflammatory bio-
markers and intracellular plasticity cascades in the per-
iphery have been consistently described in psychiatric
disorders. However, further studies using live human
peripheral cells are still important using more homoge-
neous samples and drug-naïve subjects. Also, in neuroi-
maging studies, recent techniques such as diffusion
tensor imaging (DTI) allow a comprehensive assessment
of functional connectivity and identification of biophys-
ical characteristics of white matter for mapping potential
pathways involved in human behavior. Likewise, MRS,
PET and functional studies have increased the relevance
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of human studies. These techniques allow the identifica-
tion of changes in transporters and receptors uptake,
also providing quantification of cerebral blood flow, glu-
cose metabolism and others. Finally, measurements in
resting state or during cognitive and affective tasks pro-
vide important clues on the pathophysiology of psychi-
atric disorders.
Perspectives on the translational psychiatric research
Translational research in psychiatry covers a wide range
of scientific areas, tools and technologies that aim to in-
tegrate basic research with clinical practice and to de-
velop more effective treatments. Important questions in
this context address are if advances in the field have
been translated into better therapies, as well as the po-
tential roles of biomarkers in drug development.
At present, further efforts are also required to develop
a cadre of highly qualified physician investigators who
can effectively lead multidisciplinary translational re-
search groups in psychiatry, integrating genomic science,
molecular neurobiology, and clinical investigation. At
the same time, there is an urgency to craft researchers
with technical skills able to master the intricacy and
advances in genomics, proteomics, and metabolomics, as
well as the related laboratory validation methods and ad-
equate interpretation of results. Also, standardization
and technical validation of biomarkers in psychiatry have
been modest, and still require more exploratory studies
in early drug development.
The development of translational research centers is
critical, which are expected to involve researchers with
experience in both basic and clinical sciences. Not being
able to find researchers having this profile, translational
research in psychiatry should provide an environment
that allows a direct communication between basic scien-
tists and clinicians, aiming to test hypotheses and de-
velop new models and methods. In this context, the
organization of academic teams in translational research
models may provide a continuous dialogue between
basic and clinical researchers, with exchange of experi-
ence among junior, mid-career and senior researchers
and development of centers of excellence in translational
psychiatric research.
Collaborations between academia and the private sec-
tor may involve significant resources from pharmaceut-
ical and biotechnology companies, aiming to conduct
proof of concept clinical studies in academic settings in
order to develop new effective treatments. Currently,
some pharmaceutical companies have active depart-
ments of translational psychiatry, while others did create
drug discovery programs in collaboration with univer-
sities and small biotech/biopharma start-up companies.
Mostly, industry has backed away from psychiatry until
new mechanisms, targets and compounds may increase
the probability of success. For instance, in 2007, a con-
sortium agreement called P1vital started collaboration
between industry (AstraZeneca, GlaxoSmithKline, Lund-
beck, Organon and Wyeth) and five academic clinical
psychopharmacology groups at the University of Bristol,
Cardiff University, the Institute of Psychiatry-London,
the University of Manchester and the University of Ox-
ford. This consortium aimed to define valuable healthy
volunteer models able to detect the efficacy of novel
compounds for phase 1 clinical studies [13].
The main mission is to improve the predictive validity
of potential new therapeutic agents, from preclinical
studies and throughout different stages of drug develop-
ment to clinical use and commercialization.
Translational research in psychiatry involves a bidirec-
tional continuum. The physical proximity of preclinical
and clinical research centers can facilitate logistics and
communication between researchers. Also, results from
basic research may indicate new clinical applications,
but the reverse should also be considered, ie, problems
and issues raised by clinicians may bring relevant an-
swers to better design and hypothesize basic research
projects.
Translational psychiatry is also expected to integrate
dimensional approaches to the current categorical diag-
nosis, which is going to be preliminarily shown in the
DSM-5. The goal of DSM-5 to expand “signs and symp-
toms” classification incorporating biological measures
may help to develop new multifactorial and dimensional
models able to better understand the pathophysiology of
psychiatric disorders. These models may provide insights
on the significant response rates variability and high re-
fractory rates in psychoses and affective disorders. In
other words, DSM-5 may help to develop translational
research in psychiatry by using dimensional approaches
within and across diagnostic groups in order to decrease
clinical heterogeneity and improve diagnostic validity.
The integration of dimensions with diagnostic categories
represents a promising and potentially transformative ap-
proach to DSM-5 it simultaneously addresses DSM-IV's
clinical short-comings and craft novel pathways for re-
search in neurobiology and genetics [28].
The need for personalized psychiatry is critical. For in-
stance, pharmacogenomics has shown utility in the pur-
suit of personalized approaches by the identification of
polymorphisms potentially associated with individual
clinical response and tolerability [29,30]. Also, new tech-
nologies such as microarrays, gene expression profiling
using modern platforms may provide concomitant evalu-
ation of a large number of genes with potential clinical
relevance with much lower cost than few years ago.
Promising disciplines in biomedical informatics in the
translational paradigm also include bioinformatics, im-
aging informatics, clinical informatics and public health
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information [31]. Likewise, recent advances in biostatis-
tics have provided new tools for dealing with multiple
reading problems and complex databases. These ap-
proaches may help to define who may benefit from and
who may experience side effects of a specific treatment.
Similarly, score systems for quantitative biomarkers
have also been proposed [19] and may help to decide
about future investments in phase 3 trials. Also, evalu-
ation of longitudinal clinical outcomes is important, in-
cluding long-term remission. This approach may require
a longer period of monitoring, and allow the identifi-
cation of predictors of response (only assessed at the be-
ginning of a study) and most importantly, surrogate
outcomes (e.g. biomarkers also evaluated prospectively
during the clinical follow-up and associated with clinical
response). Surrogate outcomes represent a more consist-
ent and reliable neurobiological data in order to “valid-
ate” constructs. Thus, the evaluation of psychopathology
longitudinally associated with targeted biomarkers under
a specific treatment may predict who is most likely to
respond best, in the context of personalized psychiatry.
Other aspects are relevant. The search for funding in
translational research is a major challenge to the aca-
demic community. Also, it is important to note that the
translational paradigm also considers relevant findings
with negative results. Furthermore, definition of homo-
geneous criteria about the collection, processing and
storage and retrieval of biological samples, as well as de-
velopment of scoring systems for assessment of biomar-
kers are warranted. Finally, researchers need to focus on
the identification of scientific barriers, as well as finan-
cial, ethical, regulatory and operational challenges, in-
cluding intellectual property and patent legislation, also
offering creative solutions.
Conclusions
Measuring the results of translational research in psych-
iatry does not rely only on the number of publications.
The potential success also should take into consideration
the number of citations, clinical trials, collaborations,
patents, and most importantly, the potential benefit to
patients (Figure 1). At the same time, there is a critical
need to “post-translate” results from clinical research to
medical practice, which still is limited by the long time
that takes to transform preclinical studies into medical
care.
Overall, the development of new tools and concepts
may optimize many aspects of drug discovery. These may
help to provide more consistent findings using smaller
samples in clinical studies, also decreasing trials duration
and cost. Additionally, new approaches in translational re-
search and personalized psychiatry may help to increase
efficacy rates, tolerability and expand the number of ap-
proved therapeutic options in psychiatric disorders, thus
limiting empirical treatment decision for a specific psy-
chiatric condition. The most important challenge in
translational research and personalized psychiatry is now
to translate fundamental discoveries and insights already
obtained into better preventive approaches and improved
treatments for those who need it most.
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